Wedbush Maintains an 'Outperform' on Medifast (MED); Mixed Q4; Raising Estimates on Accelerating Outlook

March 14, 2012 1:17 PM EDT
Get Alerts MED Hot Sheet
Price: $11.44 -0.35%

Rating Summary:
    4 Buy, 9 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush maintains an 'Outperform' on Medifast (NYSE: MED) price target raised from $20 to $23.

Wedbush analyst said, "Q4 revenues in line, but EPS misses on investment in new weight control centers. Q4 revenue increased 10% to $70 million, in line with our estimate. However, EPS of $0.08 was below our $0.16 estimate and the consensus estimate of $0.21, due to costs related to the opening of 10 new weight control centers and higher salaries and benefits related to personnel additions."

"We are raising our 2012 estimate for revenue to $355 million from $333 million and EPS to $1.60 from $1.53."

For an analyst ratings summary and ratings history on Medifast click here. For more ratings news on Medifast click here.

Shares of Medifast closed at $16.70 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change